Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- An innovation hub is coming to Karlsruher, thanks to a €30M investment from ZEISS.
- Desktop Genetics is looking to raise another £1.5M “for growth.”
- Omeicos is expanding in a variety of areas: it has extended its Series B, is trying to push its tech into ophthalmology, and moving to establish a subsidiary in Boston.
- Lunaphore raked in 6M CHF for its cancer tissue diagnostics aimed at hospitals and laboratories.
- The US government granted Addex $5.3M (€4.5M) to work on treatments for cocaine abuse.
- Transgene counts with a new partner, Randox, to develop multifunctional virotherapies for solid tumors.
- Cell & Gene Therapy Catapult has partnered with Forum for Innovative Regenerative Medicine in Japan to accelerate research and commercialization of regenerative therapies.
- Novadiscovery, a startup that pitched at Refresh, signed on to collaborate with Enyo Pharma in the development of its lead candidate.
- AMR has in-licensed an antibiotic candidate from Medivir in a deal of undisclosed value.
- Promethera is partnering with Shibuya to establish a cell therapy and regenerative medicine manufacturing platform.
- Noxxon has proved the concept of its lead compound NOX-A12 in combination with checkpoint inhibitors in a preclinical study.
- Vantia’s fedovapagon for nocturne met its endpoints in a Phase III trial.
- TiGenix has announced Cx601 is effective at the 52-week mark for the treatment of Crohn’s disease and will present more detailed results at ACG 2017.
- Milner Therapeutics Institute debuted a global 65 institution-strong alliance to collaborate on research in Cambridge.
- Apogenix received Orphan Designation from the European Commission for its immuno-oncology candidate asunercept to treat Myelodysplastic Syndromes.
- Sanofi & Regeneron beat back Amgen in a PCSK9 patent appeal.
Images via kunanon, warmer, nattanan726 / shutterstock.com